INTERRUPCIÓN DEL TRATAMIENTO EN NIÑOS CON INFECCIÓN CRÓNICA POR VIH

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2004-002050-66-ES

Enrollment

100

Registered

2004-11-19

Start date

2005-01-19

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

VIH-SIDA EN NIÑOS

Interventions

Pharmaceutical Form: INN or Proposed INN: ZIDOVUDINA Current Sponsor code: RETROVIR Concentration unit: mg/ml milligram(s)/millilitre INN or Proposed INN: DIDANOSINA Current Sponsor code: VIDEX Conce

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: EDAD: 2-15 AÑOS LINFOCITOS CD4 > 30 % Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: INMUNODEFICIENCIA, ES DECIR CD4 < 30 % MAL CONTROL VIROLÓGICO

Design outcomes

Primary

Measure	Time frame
Main Objective: EVALUAR LA UTILIDAD DE LAS INTERRUPCIONES PROGRAMADAS DE TRATAMIENTO EN EL MANEJO DE LOS NIÑOS CON VIH QUE HAN RESPONDIDO BIEN AL TRATAMIENTO.;Secondary Objective: EVALUAR LAS RESPUESTAS INMUNOLÓGICAS ESPECÍFICAS FRENTE AL VIH.;Primary end point(s): LINFOCITOS CD4 CARGA VIRAL	—

Countries

Spain

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026